Kangmei Pharma | 600518 - Current Liabilities


Kangmei Pharma reported CNY5.38B in Current Liabilities for its fiscal quarter ending in March of 2026.





Current Liabilities Change Date
Akebia Therapeutics USD 160.86M 13.02M Jun/2026
Alaunos Therapeutics USD 595K 218K Mar/2026
Avita Medical AUD 62.68M 77K Dec/2025
Cspc Pharmaceutical CNY 10.18B 65.36M Dec/2025
Dianthus Therapeutics USD 34.39M 3.89M Jun/2026
Genomma Lab Internacional MXN 9.39B 1.73B Jun/2026
Hypermarcas BRL 3.43B 676.7M Mar/2026
Ionis Pharmaceuticals USD 315.64M 401.36M Jun/2026
IQVIA Holdings USD 8.82B 486M Jun/2026
Jiangsu Hengrui CNY 4.25B 1.39B Jun/2026
Kangmei Pharma CNY 5.38B 433.79M Mar/2026
Moderna USD 2.53B 139M Jun/2026
Organon & Co USD 2.62B 116M Jun/2026
Revvity USD 1.28B 37.71M Jun/2026
Sh Fosun Pharma CNY 36.58B 156.4M Mar/2026
Tectonic Therapeutic USD 12.96M 3.29M Mar/2026
Viatris USD 6.35B 464.5M Jun/2026
Wuxi Apptec CNY 28.79B 9.75B Jun/2026
Xeris Pharmaceuticals USD 189.57M 70.97M Jun/2026
Zz Pientze Pharmaceu CNY 2.28B 134.52M Mar/2026